GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (ASX:AVH) » Definitions » Valuation Rank

AVITA Medical (ASX:AVH) Valuation Rank


View and export this data going back to 1993. Start your Free Trial

What is AVITA Medical Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

AVITA Medical Valuation Rank Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical (ASX:AVH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (ASX:AVH) » Definitions » Valuation Rank
Comparable Companies
INGN TLSI BFLY DCTH NPCE OM MASS SENS ZOM SMLR ABT SYK BSX MDT XTER:SHL EW DXCM SZSE:300760 XAMS:PHIA ZBH
Traded in Other Exchanges
RCEL:USA AVHHL:USA 51KB:Germany
Address
28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355
Website
https://www.avitamedical.com
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.